Fri, 12 March 2021
Diabetes Core Update Special Edition - SGLT2 Inhibitors Part 3: Beneficial Effects on Heart Failure Endpoints– March 2021
In this third episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in heart failure in persons with and without diabetes. In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for the SGLT-2 inhibitors and in episode 2 they focused on renal outcomes. This special three-part series is supported by independent educational grant from AstraZeneca.
For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.
Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health